AI English summary of an SEC filing — figures as filed
Medtronic MDTThe company said Medtronic, Inc., its indirect wholly owned subsidiary, issued €850,000,000 of 3.650% Senior Notes due 2029, €850,000,000 of 3.875% Senior Notes due 2036, €600,000,000 of 4.150% Senior Notes due 2043, and €700,000,000 of 4.150% Senior Notes due 2053 on June 3, 2024.
Key points
AI summaryThe company said Medtronic, Inc., its indirect wholly owned subsidiary, issued €850,000,000 of 3.650% Senior Notes due 2029, €850,000,000 of 3.875% Senior Notes due 2036, €600,000,000 of 4.150% Senior Notes due 2043, and €700,000,000 of 4.150% Senior Notes due 2053 on June 3, 2024.
The company said it expects Medtronic, Inc. to receive net proceeds of about €2.97 billion after deducting underwriting fees and estimated offering expenses. It said the proceeds will be used for general corporate purposes, which may include repaying outstanding commercial paper and other debt.
The company said the notes mature in 2029, 2036, 2043 and October 15, 2053. Before the applicable Par Call Date, they may be redeemed at the greater of 100% of principal and a make-whole redemption price. After the Par Call Date, they may be redeemed at 100% of principal plus unpaid interest.
The company said the notes are general unsecured senior obligations of Medtronic, Inc. and are fully and unconditionally guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc. The guarantees are structurally subordinated to the debt of Medtronic plc's subsidiaries, excluding Medtronic Luxco and Medtronic, Inc.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Medtronic prices 4 series of euro-denominated senior notes
The company said Medtronic, Inc., its indirect wholly owned subsidiary, issued €850,000,000 of 3.650% Senior Notes due 2029, €850,000,000 of 3.875% Senior Notes due 2036, €600,000,000 of 4.150% Senior Notes due 2043, and €700,000,000 of 4.150% Senior Notes due 2053 on June 3, 2024.
Source · Based on the filing body and exhibits
Net proceeds and use of funds
The company said it expects Medtronic, Inc. to receive net proceeds of about €2.97 billion after deducting underwriting fees and estimated offering expenses. It said the proceeds will be used for general corporate purposes, which may include repaying outstanding commercial paper and other debt.
Source · Based on the filing body and exhibits
Maturities and early redemption terms
The company said the notes mature in 2029, 2036, 2043 and October 15, 2053. Before the applicable Par Call Date, they may be redeemed at the greater of 100% of principal and a make-whole redemption price. After the Par Call Date, they may be redeemed at 100% of principal plus unpaid interest.
Source · Based on the filing body and exhibits
Ranking and guarantee structure of the notes
The company said the notes are general unsecured senior obligations of Medtronic, Inc. and are fully and unconditionally guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc. The guarantees are structurally subordinated to the debt of Medtronic plc's subsidiaries, excluding Medtronic Luxco and Medtronic, Inc.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…